<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440686</url>
  </required_header>
  <id_info>
    <org_study_id>HGR10I_1</org_study_id>
    <nct_id>NCT01440686</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers</brief_title>
  <acronym>HL-032</acronym>
  <official_title>A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of
      HL-032 after oral administration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum hGH(human growth hormone)concentration-time curve</measure>
    <time_frame>From 0 to the time of the last quantifiable concentration over a 32-hour sampling period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum hGH concentration</measure>
    <time_frame>Over a 32-hour sampling period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the effect(IGF-1, IGFBP-3, NEFA)curve</measure>
    <time_frame>From time 0 to the time of the last concentration(AUECO-t) over 32-hour sampling period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum IGF-1, IGFBP-3, NEFA effect</measure>
    <time_frame>Over a 32-hour sampling period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>HL-032 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose 30mg administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL-032 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose 60mg administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL-032 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose 120mg administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin</description>
    <arm_group_label>HL-032 30mg</arm_group_label>
    <arm_group_label>HL-032 60mg</arm_group_label>
    <arm_group_label>HL-032 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, oral administrations</description>
    <arm_group_label>HL-032 30mg</arm_group_label>
    <arm_group_label>HL-032 60mg</arm_group_label>
    <arm_group_label>HL-032 120mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Age(yr)between 19 and 50

          -  Signed written informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to Octreotide or hGH(human growth hormone)

          -  History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal,
             Neurological/Psychic, cancer

          -  Alcoholic, smokers or drug abusers

          -  Other conditions which in the opinion of the investigator preclude enrollment into the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Male</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

